• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

    4.705 -0.205 (-4.18%)
    Streaming Delayed Price Updated: 3:57 PM EDT, Sep 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about SciSparc Ltd. - Ordinary Shares

    < Previous 1 2
    ...
    12 13 14 15 16 17 18 19 Next >
    News headline image
    Why Is SciSparc (SPRC) Stock Up 50% Today? ↗
    SPRC stock is catapulting higher this morning as traders catch wind of SciSparc's intent to acquire a top niche product seller on Amazon. 
    Via InvestorPlace
    News headline image
    Nasdaq Surges 100 Points; Crude Oil Rises 2% ↗
    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Wednesday. 
    Via Benzinga
    News headline image
    SciSparc To Acquire Top Amazon Seller: Why SPRC Shares Are Soaring Today ↗
    SciSparc Ltd (NASDAQ: SPRC) shares are trading higher Wednesday after the company announced it entered into an agreement to acquire Wellution for $20 million. 
    Via Benzinga
    News headline image
    SciSparc To Acquire One Of Top Sellers Of Food Supplements, Cosmetics And Hemp-Based Products On Amazon ↗
    SciSparc Ltd. (NASDAQ: SPRC) signed a definitive agreement with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire its rights to purchase, Wellution, an Amazon.com (NASDAQ: 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Friday ↗
      On Friday, 122 stocks hit new 52-week lows. 
    Via Benzinga
    SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders ↗
    Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan 
    Via Benzinga
    SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome ↗
    TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd. 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Tuesday ↗
      On Tuesday, 250 stocks hit new 52-week lows. 
    Via Benzinga
    News headline image
    Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration ↗
    SciSparc Ltd. (NASDAQ: SPRC) recently announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel... 
    Via Benzinga
    SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc. ↗
    Results indicate significant decrease in cocaine craving in a sub-group that received the treatment 
    Via Benzinga
    News headline image
    Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗
    Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
    Via Benzinga
    News headline image
    Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know ↗
    Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. 
    Via Benzinga
    News headline image
    Why Are Psychedelics Stocks Up Today? ↗
    Shares of SEEL stock are in the green after the company received a grant from the Michael J. Fox Foundation to advance its SLS-004 candidate. 
    Via InvestorPlace
    News headline image
    S&P 500 Edges Higher; Nordstrom Shares Plummet ↗
    U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday. 
    Via Benzinga
    News headline image
    Dow Rises Over 100 Points; US Crude Oil Inventories Decline Higher Than Expected ↗
    U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
    Via Benzinga
    News headline image
    Why SciSparc Stock Is Skyrocketing Today ↗
    SciSparc Ltd (NASDAQ: SPRC) shares are soaring Wednesday after the company announced additional pre-clinical results of its psychedelic-based pharma collaboration for treatment of cocaine addiction... 
    Via Benzinga
    News headline image
    Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session ↗
    Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 77% to $2.35. Bright Minds priced overnight marketed offering of 2.858 million units at $1.40 per unit. 
    Via Benzinga
    News headline image
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
    We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning! 
    Via InvestorPlace
    News headline image
    Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket ↗
    Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share. 
    Via Benzinga
    News headline image
    This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday ↗
    Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Monday ↗
      On Monday, 31 companies hit new 52-week lows. 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Friday ↗
      On Friday, 39 companies reached new 52-week lows. 
    Via Benzinga
    News headline image
    These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches ↗
    More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050. 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Thursday ↗
      On Thursday, 108 companies set new 52-week lows. 
    Via Benzinga
    News headline image
    SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome ↗
    SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of... 
    Via Benzinga
    News headline image
    SciSparc Announces Buyback Equal To 12% Of Float ↗
    SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par... 
    Via Benzinga
    News headline image
    Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.
    NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
    From Traders News Source
    Via AccessWire
    News headline image
    SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome ↗
    SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study... 
    Via Benzinga
    News headline image
    SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome ↗
    SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed... 
    Via Benzinga
    R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
    Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
    Via FinancialNewsMedia
    < Previous 1 2
    ...
    12 13 14 15 16 17 18 19 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.